“Oestrogen skincare” is becoming its own category — and two very different products share the name

The regulatory ground shifted first. In November 2025 the FDA announced it would strip the “black box” warning — covering cardiovascular disease, breast cancer and probable dementia — from menopausal hormone therapy labels, and by February 2026 it had approved the reworded labels for a first batch of six products, among them Bijuva, Divigel, Prometrium and Estring. The endometrial cancer warning stays on systemic oestrogen-alone therapy for women who still have a uterus, and the new labelling leans on timing: starting before 60, or within ten years of menopause. Dermatology noticed. Skin had always been a footnote in the hormone conversation, and suddenly there was room for it.

There’s a reason skin keeps coming up. The American Society of Plastic Surgeons puts the loss at up to 30% of dermal collagen in the first five years after menopause, then roughly 2% a year after that — steeper than ordinary ageing explains. It’s also strikingly under-discussed: in a survey of 463 postmenopausal women aged 42 to 83 published in the journal Cosmetics, around 47% said nobody had ever told them menopause would affect their skin, hair and nails, and more than half felt it had knocked their self-esteem. That was a self-selected online questionnaire in a single country, so read it as a signal about how little gets said, not as a precise national figure.

Here’s the part the marketing blurs. Two quite different things are sold as “oestrogen skincare”. The first is genuine topical oestrogen — bio-identical estradiol, or the weaker estriol for more sensitive skin. These are real hormones with real effects and a real side-effect list: irritation, hormonal acne, unwanted hair growth, hyperpigmentation. They belong in a prescriber’s hands. The second is MEP (methyl estradiolpropanoate), which isn’t an oestrogen at all. It activates oestrogen receptors in skin cells but enters the bloodstream as an inactive metabolite — that’s the entire design goal, the receptor effect without systemic hormonal activity. It’s sold as a cosmeceutical, not approved by the FDA as an anti-ageing drug. The two aren’t interchangeable, and the word “oestrogen” on a box tells you almost nothing about which one you’re holding.

The evidence for MEP is genuinely early. The most-cited trial is an open-label study of 31 women who had been without periods for at least a year: 26 of them (84%) improved, clinician-rated improvement averaged 21%, and self-reported satisfaction with the eye area rose 47%, with no significant side effects reported. Encouraging — but open-label with no control group means the placebo response can’t be separated out, and in cosmetic studies that response is large. A small double-blind randomised pilot against vehicle also exists. What doesn’t exist yet is a large, long, properly controlled trial.

In-clinic treatments are being repositioned the same way. Galderma has released interim data from an investigator-initiated study led by Andreas Nikolis at McGill, pairing Restylane Skinboosters with Sculptra on menopausal skin: hydration, skin-barrier measures and patient satisfaction all improved, satisfaction peaked at six months, and the order mattered — skinboosters first gave the best hydration results. Worth knowing, and worth discounting appropriately: it’s interim, industry-supported, announced by press release rather than peer review, and no control arm has been reported. None of it replaces the unglamorous basics that do have good evidence behind them — daily sunscreen, a retinoid, topical vitamin C. And systemic HRT still isn’t a skincare decision. If you’re considering topical hormones, that’s a conversation with a clinician, particularly if you have a history of hormone-sensitive cancer: the ASPS guidance lists breast cancer patients on aromatase inhibitors as candidates only with their oncologist’s sign-off.

What the research says